Portal de Periódicos da CAPES

Consenso Mexicano para el Tratamiento de la Hepatitis C

2018; Elsevier BV; Volume: 83; Issue: 3 Linguagem: Inglês

10.1016/j.rgmx.2017.11.001

2255-5528

I. Aiza-Haddad, A. Ballesteros-Amozurrutia, Omar D. Borjas‐Almaguer, M. Castillo-Barradas, Graciela Castro‐Narro, Norberto C. Chávez‐Tapia, R.A. Chirino-Sprung, L.E. Cisneros-Garza, Margarita Dehesa-Violante, J. Flores-Calderón, A. Flores-Gaxiola, Ignacio García‐Juárez, M.S. González-Huezo, E.I. González-Moreno, Fatima Higuera‐de la Tijera, David Kershenobich, Eric López-Méndez, R. Malé-Velázquez, E Marín-López, José Antonio Mata‐Marín, Nahúm Méndez‐Sánchez, Roberto Monreal‐Robles, R. Moreno-Alcántar, Linda E. Muñoz‐Espinosa, S. Navarro-Alvarez, Noris Pavía-Ruz, Alma Minerva Pérez-Ríos, J.L. Poo-Ramírez, M.T. Rizo-Robles, J.F. Sánchez-Ávila, Ricardo Sandoval-Salas, Aldo Torre, R. Torres-Ibarra, R. Trejo-Estrada, J.A. Velarde-Ruiz Velasco, E. Wolpert-Barraza, Francisco Bosques‐Padilla,

Hepatitis B Virus Studies

The aim of the Mexican Consensus on the Treatment of HepatitisC was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitisC treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary.